BIOGEN INC. is 5.9x more valuable than CG Oncology, Inc. by market capitalization ($28.73 B vs $4.84 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CGON | BIIB |
|---|---|---|
| Market cap | $4.84 B | $28.73 B |
| US-listed rank | #1405 | #480 |
| Revenue (latest FY) | $4.04M | $9.89B |
| Net income (latest FY) | -$161.00M | $1.29B |
| Net margin | -3985.1% | 13.1% |
| P/E (trailing FY) | - | 22.2 |
| SEC filings | 189 | 2,690 |
BIOGEN INC. is 5.9x more valuable than CG Oncology, Inc. by market capitalization ($28.73 B vs $4.84 B).
In their latest fiscal years, CG Oncology, Inc. reported $4.04M in revenue while BIOGEN INC. reported $9.89B.
Full pages: CG Oncology, Inc. and BIOGEN INC., or browse the full rankings.